Summary: Excessive exposure to certain antibiotics can predispose a person to Parkinson’s disease, with a delay of onset of up to 15 years.
Source: University of Helsinki
Higher exposure to commonly used oral antibiotics is linked to an increased risk of Parkinson’s disease according to a recently published study by researchers from the Helsinki University Hospital, Finland.
The strongest associations were found for broad-spectrum antibiotics and those that act against anaerobic bacteria and fungi. The timing of antibiotic exposure also seemed to matter.
The study suggests that excessive use of certain antibiotics can predispose to Parkinson’s disease with a delay of up to 10 to 15 years. This connection may be explained by their disruptive effects on the gut microbial ecosystem.
“The link between antibiotic exposure and Parkinson’s disease fits the current view that in a significant proportion of patients the pathology of Parkinson’s may originate in the gut, possibly related to microbial changes, years before the onset of typical Parkinson motor symptoms such as slowness, muscle stiffness and shaking of the extremities. It was known that the bacterial composition of the intestine in Parkinson’s patients is abnormal, but the cause is unclear. Our results suggest that some commonly used antibiotics, which are known to strongly influence the gut microbiota, could be a predisposing factor,” says research team leader, neurologist Filip Scheperjans MD, PhD from the Department of Neurology of Helsinki University Hospital.
In the gut, pathological changes typical of Parkinson’s disease have been observed up to 20 years before diagnosis. Constipation, irritable bowel syndrome and inflammatory bowel disease have been associated with a higher risk of developing Parkinson’s disease. Exposure to antibiotics has been shown to cause changes in the gut microbiome and their use is associated with an increased risk of several diseases, such as psychiatric disorders and Crohn’s disease. However, these diseases or increased susceptibility to infection do not explain the now observed relationship between antibiotics and Parkinson’s.
“The discovery may also have implications for antibiotic prescribing practices in the future. In addition to the problem of antibiotic resistance, antimicrobial prescribing should also take into account their potentially long-lasting effects on the gut microbiome and the development of certain diseases,” says Scheperjans.
The possible association of antibiotic exposure with Parkinson’s disease was investigated in a case-control study using data extracted from national registries. The study compared antibiotic exposure during the years 1998-2014 in 13,976 Parkinson’s disease patients and compared it with 40,697 non-affected persons matched for the age, sex and place of residence.
Antibiotic exposure was examined over three different time periods: 1-5, 5-10, and 10-15 years prior to the index date, based on oral antibiotic purchase data. Exposure was classified based on number of purchased courses. Exposure was also examined by classifying antibiotics according to their chemical structure, antimicrobial spectrum, and mechanism of action.
Funding: The authors have received funding from The Finnish Parkinson Foundation, The Finnish Medical Foundation, The Maire Taponen Foundation, and The Academy of Finland (295724, 310835). The funders had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or the decision to submit the article for publication.
Relevant conflicts of interests/financial disclosures: F.S. is listed as inventor on patents FI127671B and US10139408B2 and patent applications EP3149205A4 and US16/186,663. F.S. is founder and chief executive officer of NeuroInnovation Oy. The authors report no other conflicts of interest relative to the research covered in this manuscript.
About this neuroscience research article
Source: University of Helsinkir Media Contacts: Filip Scheperjans – University of Helsinki Image Source: The image is in the public domain.
Antibiotic exposure and risk of Parkinson’s disease in finland: A nationwide case‐control study
Background Gut microbiota alterations have been found in prodromal and established Parkinson’s disease (PD). Antibiotic exposure can have long‐term effects on the composition of human intestinal microbiota, but a potential connection between antibiotic exposure and risk of PD has not been studied previously.
Objective To evaluate the impact of antibiotic exposure on the risk of PD in a nationwide, register‐based, case‐control study.
Methods We identified all patients who were diagnosed with PD in Finland during the years 1998 to 2014. Information was obtained on individual purchases of orally administered antibiotics during the years 1993 to 2014. We assessed the association between prior antibiotic exposure and PD using conditional logistic regression.
Results The study population consisted of 13,976 PD cases and 40,697 controls. The strongest connection with PD risk was found for oral exposure to macrolides and lincosamides (adjusted odds ratio up to 1.416; 95% confidence interval, 1.053–1.904). After correction for multiple comparisons, exposure to antianaerobics and tetracyclines 10 to 15 years before the index date, sulfonamides and trimethoprim 1 to 5 years before the index date, and antifungal medications 1 to 5 years before the index date were positively associated with PD risk. In post hoc analyses, further positive associations were found for broad‐spectrum antibiotics.
Conclusions Exposure to certain types of oral antibiotics seems to be associated with an elevated risk of PD with a delay that is consistent with the proposed duration of a prodromal period. The pattern of associations supports the hypothesis that effects on gut microbiota could link antibiotics to PD, but further studies are needed to confirm this.